At Bisc Therapeutics, we are developing first-in-class therapies to preserve vision and prevent blindness in millions of patients with retinal degenerative diseases. Our groundbreaking Bax inhibitor technology protects retinal cells by halting retinal cell death at its core, offering a transformative solution for a range of conditions, including age-related macular degeneration, glaucoma, and inherited retinal disorders. With our orally-available treatment, we aim to improve patient outcomes and quality of life without the need for invasive eye injections.